NASH therapies head toward landmark approval
On 19 May, advisors to the US Food and Drug Administration will meet virtually to discuss whether the antifibrotic benefits of a drug called Ocaliva from Intercept Pharmaceuticals outweigh the
toxicity risks for patients with this common fatty liver disease. A full regulatory decision is expected a month later. Approval of a second drug, resmetirom from Madrigal Pharmaceuticals, could soon follow.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
From science fiction to reality: Xenobots are redefining biotechnologyThe xenobot had been predicted to be a valuable tool in medicine and other fields. It is expected not only to help treat cancer but keep the aquatic bodies clean.
続きを読む »
Organization helps connect military members and veterans to nature and each otherThe Fallen Outdoors is an organization throughout the country that helps connect veterans and active duty military members through fishing, hunting, and hiking trips.
続きを読む »
‘I’m a Urologist, and Here’s What It Means if You’re Very Good at Holding Your Pee’It's a little bit of nature and a little bit of nurture.
続きを読む »
HIGH CRIMES: Sheriff says drugs are fueling the crime crisis in CaliforniaA California sheriff accused lawmakers of refusing to acknowledge the impact of permissive drug laws on rising crime. But how intertwined are the two issues?
続きを読む »
BC man arrested for selling illegal drugs from mobile shopAs Washington’s drug laws face an uncertain future, a Canadian man is trying a different tactic to fight back against deadly overdoses — using his mobile shop to sell heroin, cocaine, meth, and other drugs in Vancouver B.C.
続きを読む »